Topical milrinone or nitroglycerin studied for internal mammary artery flow in CABG patients

Status: COMPLETED | Phase: PHASE3 Condition(s): Internal Mammary Artery Syndrome, Vasodilation Intervention(s): The topical application of a vasodilator on the LIMA graft (DRUG) Forty-six consecutive patients undergoing elective primary coronary artery bypass grafting were enrolled. After the left IMA was harvested, free flow was measured under controlled hemodynamic conditions before any intervention (flow 1) and at a mean of 12.5 minutes after the topical application of one of three agents (milrinone, nitroglycerin or normal saline) on the IMA (flow 2). Detailed: Fifty consecutive patients undergoing elective primary coronary artery bypass grafting were enrolled in this study. Patients were randomly assigned to receive the topical application of one of three agents: milrinone (Baxter Pharmaceuticals, Ahmedabad, India) 10 mg in 20 ml of dextrose 5%, nitroglycerin (Caspian Tamin Pharmaceutical, Guilan, Iran) 10 mg in 20 ml of normal saline, or normal saline (0.9% sodium chloride solution) as control. All surgical procedures and measurements were carried out by a single surgeon who was blinded to the topical agent which was applied. Each patient enrolled in the study gave a written informed consent, and the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the local human resear Primary Outcome(s): LIMA free flow Enrollment: 46 (ACTUAL) Lead Sponsor: Damascus University Start: 2022-01-01 | Primary Completion: 2023-01-31